222 related articles for article (PubMed ID: 37725308)
1. Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review.
Dmochowski RR; Newman DK; Rovner ES; Zillioux J; Malik RD; Ackerman AL
Adv Ther; 2023 Nov; 40(11):4741-4757. PubMed ID: 37725308
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
3. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
Chen JV; Gahn JC; Nesheim J; Mudd PN
Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
[TBL] [Abstract][Full Text] [Related]
4. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
5. The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists.
Welk B
Eur Urol Focus; 2023 Jan; 9(1):168-171. PubMed ID: 35987891
[TBL] [Abstract][Full Text] [Related]
6. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.
Dmochowski RR; Rovner ES; Kennelly MJ; Newman DK; Abedinzadeh L; Snyder D; Thomas E; Haag-Molkenteller C; Rosenberg MT
BMC Urol; 2023 Apr; 23(1):64. PubMed ID: 37095473
[TBL] [Abstract][Full Text] [Related]
7. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
Fogaing C; Mossa AH; Campeau L
Curr Urol Rep; 2020 Oct; 21(12):49. PubMed ID: 33090278
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of providers who prescribed only anticholinergic medications for overactive bladder in 2020.
Carr DN; Macharia A; Hacker MR; Winkelman WD
Am J Obstet Gynecol; 2023 Sep; 229(3):316.e1-316.e7. PubMed ID: 37244459
[TBL] [Abstract][Full Text] [Related]
10. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
11. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
Thiagamoorthy G; Giarenis I; Cardozo L
Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
[TBL] [Abstract][Full Text] [Related]
12. Vibegron: a β
Paton DM
Drugs Today (Barc); 2021 Aug; 57(8):507-517. PubMed ID: 34405208
[TBL] [Abstract][Full Text] [Related]
13. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
[TBL] [Abstract][Full Text] [Related]
14. Inequities in Filled Overactive Bladder Medication Prescriptions in the US.
Luchristt D; Bretschneider CE; Kenton K; Simon M; Brown O
JAMA Netw Open; 2023 May; 6(5):e2315074. PubMed ID: 37223899
[TBL] [Abstract][Full Text] [Related]
15. Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
Minhas R; Tadrous M; Elterman D; Gomes T
Neurourol Urodyn; 2018 Jun; 37(5):1693-1700. PubMed ID: 29682790
[TBL] [Abstract][Full Text] [Related]
16. Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options.
Escobar CM; Falk KN; Mehta S; Hall EF; Menhaji K; Sappenfield EC; Brown OE; Ringel NE; Chang OH; Tellechea LM; Barnes HC; Jeney SES; Bennett AT; Cardenas-Trowers OO
Obstet Gynecol; 2021 Mar; 137(3):454-460. PubMed ID: 33543891
[TBL] [Abstract][Full Text] [Related]
17. Current and future pharmacotherapy for treating overactive bladder.
Thiagamoorthy G; Cardozo L; Robinson D
Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.
Oefelein MG
Drug Saf; 2011 Sep; 34(9):733-54. PubMed ID: 21830836
[TBL] [Abstract][Full Text] [Related]
19. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
20. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
Rai BP; Cody JD; Alhasso A; Stewart L
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
